{"id":145156,"date":"2010-01-06T11:31:53","date_gmt":"2010-01-06T16:31:53","guid":{"rendered":"http:\/\/blogs.wsj.com\/health\/2010\/01\/06\/pfizer-like-much-of-big-pharma-pushes-further-into-generics\/"},"modified":"2010-01-06T11:31:53","modified_gmt":"2010-01-06T16:31:53","slug":"pfizer-like-much-of-big-pharma-pushes-further-into-generics","status":"publish","type":"post","link":"https:\/\/mereja.media\/index\/145156","title":{"rendered":"Pfizer, Like Much of Big Pharma, Pushes Further Into Generics"},"content":{"rendered":"

\"Pfizer\"The distance between Big Pharma and the generic drugs business keeps getting narrower. Under a deal with an Indian drugs shop Strides Arcolab<\/a>, Pfizer will add some 40 off-patent drugs, including many cancer medicines, to the list of products it sells in the U.S. Here’s a statement<\/a> Pfizer put out describing the deal.<\/p>\n

Pfizer’s been moving in this direction for a while now. An “established products<\/a>” division the company set up back in 2008 to focus on off-patent drugs now sells some 600 products, and the company has cut several deals like the one announced today. (See the 2008 deal with Aurobindo India<\/a>, for example.)<\/p>\n

Growth has slowed in the branded-drugs business, and the push is on in the developed world to slow the rise of health-care costs. Both of those factors are driving many of the big names in the drugs business to move further into generics. In the past few years, GlaxoSmithKline made a deal<\/a> with the South African drug-maker Aspen to sell off-patent drugs in the developing world, Sanofi-Aventis bought several generics companies<\/a>, and Merck set up a unit<\/a> to sell copies of off-patent biotech drugs.<\/p>\n

Photo: Associated Press<\/em><\/p>\n

<\/img><\/a>
\n<\/img><\/a><\/p>\n

\n<\/img><\/a> <\/img><\/a> <\/img><\/a> <\/img><\/a> <\/img><\/a>\n<\/div>\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

The distance between Big Pharma and the generic drugs business keeps getting narrower. Under a deal with an Indian drugs shop Strides Arcolab, Pfizer will add some 40 off-patent drugs, including many cancer medicines, to the list of products it sells in the U.S. Here’s a statement Pfizer put out describing the deal. Pfizer’s been […]<\/p>\n","protected":false},"author":650,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-145156","post","type-post","status-publish","format-standard","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/145156","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/users\/650"}],"replies":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/comments?post=145156"}],"version-history":[{"count":0,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/145156\/revisions"}],"wp:attachment":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/media?parent=145156"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/categories?post=145156"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/tags?post=145156"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}